CoVID-19 Molecular screening for Institutions and individuals
Schedule your CoVID-19 test - We aim to provide the result in 24 hours
Check this page for information on NANO4 CoVID-19 molecular screening service
(service applies only to Portugal)
Despiste molecular da CoVID-19 para Instituições e indivíduos
Marque o seu teste, nos desenvolve-mo-lo para si
Temos como objectivo fornecer o resultado em 24 horas.
Nano4 Global
Fast and affordable colorimetric precision nanodiagnostics
Nano4 Global is a young start-up launched in 2015 to market innovative nanotechnology based molecular diagnostics.
Nano4 is pioneering a new high-confidence proprietary nanotechnology platform relying on more than 12 years of research and development at Universidade NOVA de Lisboa - Science and Technology, Department of Life Sciences.
Our Values and Quality Policy
NANO4 is ISO 13485:2016 and ISO 9001:2015 Certified Company
NANO4 Global is ISO 13485:2016 and ISO 9001:2015 certified company, the higher level of ISO standards. These certifications are a requirement for regulatory purposes. ISO 13485:2016 is an international standard that outlines the requirements for a quality management system specific to the medical devices industry.
Certifications
2020 - flashback in pandemic context
An extraordinary year for Nano4 Global - all objectives achieved and start of molecular diagnostics for CoVID-19.
read more
Nano4 Industrial facility
Nano4 Global has a fully dedicated manufacturing lab. Located near Lisbon within a pharmaceutical campus hosting a Portuguese pharma company in Portugal. Nano4 Global manufacturing capability offer molecular diagnostic production and custom nanotechnology proficiency.
Nano4 Platform
How It Works
NANO4 Platform relies on a colorimetric molecular diagnostic method based on gold nanoparticles that provide fast and specific identification of a DNA or RNA biomarker.
NANO4 platform provides a colorimetric molecular diagnostic method based on gold nanoprobes that allow fast and specific identification of a DNA or RNA biomarker. The friendly use of Nano4 nanodiagnostics puts forward a fast, accurate, affordable technology - the next generation of molecular nanodiagnostics.
NANO4 is the next generation of molecular nanodiagnostics applied to life sciences that provides simple readout depending on the biomarker.
NANO4 is an award winning technology - Santander Totta/NOVAScientific Prize.
Gold nanoprobes provide a visual
colorimetric change to identify
the desired DNA/RNA sequence.
Advantages
- fast colorimetric output
- accurate
- affordable and user friendly
(no dedicated apparatus needed)
Turn Around Time
Due to the easy and simple operation, NANO4 will impact the way molecular diagnostics are performed and will lead the decentralization of molecular diagnostics - from genetics lab to point of need.
Visual Colorimetric Change
| BLANK |
|
|
|
Gold nanoprobes provide a
visual colorimetric change
that identifies a DNA/RNA
sequence.
|
| POSITIVE |
|
|
|
Target DNA/RNA prevents aggregation.
Solution remains
RED after revelator.
|
| NEGATIVE |
|
|
|
Gold nanoprobes aggregates
in contact with a revelator.
color changes
RED to BLUE
|
| BLANK |
|
|
|
|
|
Gold nanoprobes provide a
visual colorimetric change
that identifies a DNA/RNA
sequence.
|
| POSITIVE |
|
|
|
|
|
Target DNA/RNA prevents aggregation.
Solution remains
RED after revelator.
|
| NEGATIVE |
|
|
|
|
Gold nanoprobes aggregates
in contact with a revelator.
color changes
RED to BLUE
|
More/ Published data
Clin Chem. 2006. doi: 10.1373/clinchem.2005.065391
Nanotechnology. 2010 Oct. doi: 10.1088/0957-4484/21/41/415101
Tuberculosis (Edinb). 2014. doi: 10.1016/j.tube.2013.12.009
Anal Bioanal. Chem. 2016. doi: 10.1007/s00216-016-9622-9
Pipeline
Diagnostic Focus
NANO4 platform is extremely flexible and easily adapted to a range of applications where specific DNA or RNA sequence is critical, such as detection of human pathogens (validation ongoing for M. tuberculosis, Zika), selected cancers and other genetic diseases.
|
|
|
R&D
|
Design
|
Development
|
Clinical Validation
|
|
|
|
|
TB
Zika
Leukaemia
Undisclosed Prog.
|
Team
Executive Management
Our combination of expertise in Science, industry and operations allows us to realize the immense potential of our technology. Together, Nano4 Global team accumulates more than 30 years of experience in the life sciences, from, research, start-ups to operations and management.
Pedro V. Baptista, PhD
CSO
15 years of Leading research in Nanotechnoloy Diagnostics / Thereapeutics.
Strong commitment to SMEs via EU funded instruments and joint funded projects; acting as expert for international science Boards.
more information >
Filipe Assoreira
CEO
12 years multi-country corporate experience in Genzyme, including Country Manager and International Management.
President of Portugal’s Biotech Industry Organization, MBA and Pharma Degree.
more information >
Alexandra Fernandes, Phd
COO
5 years experience in clinical diagnostic in corporate environment, Founder of 2 successful SMEs, including Molecular Diagnostics Start up built upon 10 years of molecular genetics research.
more information >
Careers
We always seek for strong leaders and top scientists that want to change our world.
Please submit your application
Media
News & Updates
July 2021
NANO4 in partnership with CUF Hospitals and Clinics network initiates validation of diagnostics platform for Chronic Myeloid Leukaemia
January 2021
2020 - flashback in pandemic context
July 2020
Nano4 awarded with P2020 Grant
February 2020
2019, a year to remember
November 2019
NANO4 was recognized with the NOVA SPIN-OFF seal
Awards and grants
Granted with SME phase 2 in 2018: 1,4 M€ grant
Granted with SME phase 1 in 2017
Granted with P2020 non-dilutive fund in 2018
Appointed as one of the 30 most innovative companies in Portugal at NOS Awards 2017
One of the 66 companies selected to the programme Road to Websummit 2016
Gold Nanoparticles Platform was recognized in 2012 with Santander Totta / Universidade Nova Lisboa awarded of technology
×
![]()
